Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)

PURPOSE: Glioblastoma (GBM) has a poor prognosis after standard treatment. Recently, metformin has been shown to have an antitumor effect on glioma cells. We performed the first randomized prospective phase II clinical trial to investigate the clinical efficacy and safety of metformin in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Wan-Soo, Chang, Jong Hee, Kim, Jeong Hoon, Kim, Yu Jung, Jung, Tae-Young, Yoo, Heon, Kim, Se-Hyuk, Ko, Young-Cho, Nam, Do-Hyun, Kim, Tae Min, Kim, Se Hoon, Park, Sung-Hae, Lee, Youn Soo, Yim, Hyeon Woo, Hong, Yong-Kil, Yang, Seung Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244311/
https://www.ncbi.nlm.nih.gov/pubmed/37278858
http://dx.doi.org/10.1007/s12672-023-00678-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244311/
https://www.ncbi.nlm.nih.gov/pubmed/37278858
http://dx.doi.org/10.1007/s12672-023-00678-3

Ejemplares similares